Exasol’s High-Performance Database Now Available as SaaS Model
Exasol has today announced that its high-performance analytics database is now available through a software-as-a-service (SaaS) model on Amazon Web Services (AWS). Exasol’s SaaS offering, initially available in two versions, provides businesses the high performance and ease of use that Exasol is known for without them having to manage their own hardware infrastructure. Exasol, named Technology Partner of the Year 2021 in DACH by AWS, worked extensively with AWS SaaS Factory to deliver its SaaS model.
“As a company focused completely on superior analytics performance, we want to be able to provide businesses the same impressive experience wherever their data goes. It’s exactly for this reason that we are building a bridge for organizations to be able to move analytics processes to the cloud without risk, without friction, and without taking performance hits - something that Exasol is uniquely placed to offer,” said Mathias Golombek, CTO of Exasol. “As part of this, AWS gives us the ideal platform to build out our SaaS solution. It allows us to separate the compute from the storage, meaning we can elastically scale up and down compute power to optimize the costs and workloads for our customers.”
Exasol’s deep technical partnership with AWS has been key to ensure it can deliver the best-in-class performance via its SaaS offering. For Exasol, as an in-memory database, the ability to seamlessly increase or decrease its memory footprint is important. The AWS cloud platform provides Exasol with the ability to scale both vertically and horizontally to meet its needs. Furthermore, as Exasol seamlessly manages hot and cold data between the object store, local SSDs and main memory, AWS provides Exasol with the infrastructure to do that without compromising performance.
“We understand the immense challenges facing companies in terms of extracting value from data to drive their business. We believe that companies who master this discipline will be better equipped for long-term success. Performance and cost are key drivers of any successful data strategy, and we are extremely proud to now offer our world-class performance technology through a consumption-based SaaS model on AWS for customers looking to move away from slow and costly systems without disruption to their business,” said Aaron Auld, CEO of Exasol. “Our technology is perfectly suited to solving the challenges that come with implementing cloud-first strategies while minimizing risk. Exasol’s SaaS offering is a key step towards delivering best-in-class performance combined with immediate budget relief to our customers.”
With Exasol’s SaaS offering, customers can be up and running in a matter of minutes, in a fully managed system, while still benefiting from the best-in-class high-performance database technology that Exasol is known for without compromising security. When deployed in a public cloud, Exasol leverages native security measures such as AWS IAM or Active Directory services, as well as built-in security features. For customers who prefer to manage their own cloud solution, Exasol can also run on their cloud of choice, and for those looking for the ultimate control over their data, customers can continue to run Exasol on-premises. A hybrid solution is also possible for those customers who have needs that span several environments. Exasol is working to deliver a model which allows customers to select the appropriate deployment for different workloads, depending on regulatory considerations and their business needs. The launch of the SaaS model is the next step in this direction.
Andy Hayler, CEO of the Information Difference commented on the announcement: “Whilst cloud computing is a foundation for many businesses, especially digital ones, most organizations are yet to move fully to the cloud. Exasol is providing customers the best of both worlds with its SaaS offering, offering them freedom to undertake a hybrid cloud strategy and migrate at their own pace. By not focusing on a 'cloud-only' approach to its solutions Exasol enables customers to derive business value from their data quickly, easily and cost effectively, no matter where they choose to store their data, based on a high performance, flexible and scalable platform.”
About Exasol
Exasol was founded in 2000 with the vision to transform how organizations use data. Today, Exasol’s analytics database – the fastest in the world – is trusted by the world’s most ambitious organizations. With offices in several locations across the US and Europe, Exasol is committed to delivering flexible, scalable and powerful analytics solutions to customers wherever they are, in the cloud – public or private - or on-premises.
Exasol – accelerating insights from the world’s data.
Learn more at: www.exasol.com and follow us on social media: LinkedIn and Twitter.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220203005141/en/
Contact information
PR:
Isabella Alder, EMEA Communications Manager at Exasol
Email:isabella.alder@exasol.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 11:36:00 CEST | Press Release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 19:00:00 CEST | Press Release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
Incyte to Highlight Early-Stage Oncology Data at American Association for Cancer Research Annual Meeting 202525.4.2025 14:00:00 CEST | Press Release
Incyte (Nasdaq:INCY) today announced that the Company will present new early-stage data from its oncology portfolio at the American Association of Cancer Research (AACR) Annual Meeting 2025 in Chicago, IL, from April 25–30. “At AACR we will be presenting data from early-stage programs across our oncology portfolio, including for patients with myeloproliferative neoplasms, ovarian cancer and other solid tumors,” said Pablo J. Cagnoni, M.D., President and Head of Research and Development, Incyte. “These data will guide our approach as we advance our pipeline and seek to transform the treatment landscape for patients with cancer and myeloproliferative neoplasms.” Abstracts accepted for presentation at AACR include: Mini Symposium INCB177054 INCB177054: A Novel, Potent, Orally Bioavailable DGKα/ζ Dual Inhibitor Enhances T-Cell Function and Demonstrates Potent Antitumor Activity (Session Title: Novel Antitumor Agents. April 28, 4:50 p.m. – 5:05 p.m. ET (3:50 p.m. – 4:05 p.m. CT). Abstract #
SLB Announces First-Quarter 2025 Results; Remains Committed to Return a Minimum of $4 Billion to Shareholders in 202525.4.2025 12:50:00 CEST | Press Release
SLB (NYSE: SLB) today announced results for the first-quarter 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250423635499/en/ The exterior of the SLB headquarters in Houston, Texas. First-Quarter Results (Stated in millions, except per share amounts) Three Months EndedChange Mar. 31, 2025 Dec. 31, 2024 Mar. 31, 2024 Sequential Year-on-year Revenue $8,490 $9,284 $8,707 -9% -3% Income before taxes - GAAP basis $1,063 $1,387 $1,357 -23% -22% Income before taxes margin - GAAP basis 12.5% 14.9% 15.6% -241 bps -306 bps Net income attributable to SLB - GAAP basis $797 $1,095 $1,068 -27% -25% Diluted EPS - GAAP basis $0.58 $0.77 $0.74 -25% -22% Adjusted EBITDA* $2,020 $2,382 $2,057 -15% -2% Adjusted EBITDA margin* 23.8% 25.7% 23.6% -186 bps 18 bps Pretax segment operating income* $1,556 $1,918 $1,649 -19% -6% Pretax segment operating margin* 18.3% 20.7% 18.9% -232 bps -60 bps Net income attributable to SLB, excluding charges &
Corona, The World’s Most Valuable Beer Brand 1 , Announces Its 100-Year Anniversary with Global Celebration25.4.2025 10:00:00 CEST | Press Release
Today, Corona proudly celebrates its 100-year anniversary, a remarkable milestone for the iconic brand that has been synonymous with the beach and enjoyed by consumers worldwide for the past century. Since 1925, Corona has cultivated a deep association with the beach; fully embodying a lifestyle connected to nature and relaxation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425804516/en/ Corona 100 This Is Living Since 1925 In honor of the occasion, Corona invites everyone to live their “beach side” – a.k.a. their best side – at top-tier beach locations across the globe. The Corona 100 platform includes a film highlighting 100 years of beach culture, a definitive list of the top 100 beaches in the world to visit, and a signed multi-year sponsorship of a renowned concert at Copacabana Beach in Rio de Janeiro — all offering people across the globe opportunities to connect with their beach side. “For 100 years, Corona has
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom